

## Special Issue

# Cognitive Outcomes in Cancer: Recent Advances and Challenges

### Message from the Guest Editors

Cancer-related cognitive impairment (CRCI), formerly known as ‘chemobrain’, is a prevalent, bothersome, and potentially debilitating problem for survivors for their lifespan. Despite its prevalence, research is relatively limited, and questions remain regarding associated risk factors, underlying mechanisms, and potential interventions to address CRCI. Research is needed to fully understand patients most at risk for CRCI for informed decision-making. We encourage contributions that are focused on, but not limited to, the following themes:

- Biomarkers
- Genetic markers
- Associated Risk Factors including social determinants of health and/or vulnerable populations (e.g., children, adolescent and young adults, and older cancer survivors)
- Neuroimaging
- Cognitive Rehabilitation—Cognitive Training, Cognitive Behavioral Therapy, etc.
- Stress-reducing therapies—Mindfulness-based stress reduction, exercise, etc.
- Pharmacological interventions
- Impact on health-related quality of life

We look forward to receiving your contributions.

---

### Guest Editors

Prof. Dr. Diane Von Ah

Prof. Dr. Alexandre Chan

Prof. Dr. Brenna C. McDonald

---

### Deadline for manuscript submissions

closed (15 September 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.4**  
**CiteScore 8.8**  
**Indexed in PubMed**



[mdpi.com/si/137526](https://mdpi.com/si/137526)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)